Navigation Links
ViroPharma Incorporated Honored by the National Organization for Rare Disorders
Date:5/18/2009

prove the lives of people with rare diseases. NORD represents the nearly 30 million Americans who have rare diseases.

About Cinryze(TM) (C1 esterase inhibitor (human))

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product that has been approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. C1 inhibitor therapy has been used acutely for more than 35 years in Europe to treat patients with C1 inhibitor deficiency.

Cinryze has been generally well tolerated. The most common adverse reactions observed have been upper respiratory infection, sinusitis, rash and headache. No drug-related serious adverse events (SAEs) have been observed in clinical trials. Severe hypersensitivity reactions may occur. Thrombotic events have occurred in patients receiving high dose off-label C1 inhibitor therapy well above the approved treatment dosage regimen. With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening patients for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.

Cinryze is for intravenous use only. A dose of 1000 Units of Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.

About Hereditary Angioedema

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contac
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. ViroPharma to Present at the BIO CEO & Investor Conference
4. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. ViroPharma To Acquire Lev Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Ceres, Inc . (Nasdaq: CERE ), an ... for the three months ended May 31, 2014 and ... reported that the company and its customers have made ... Brazil, which concluded in June, despite dry and hot ... part of the growing season. Yields of several of ...
(Date:7/10/2014)... PNAS (Proceedings of the National Academy of Sciences) ... deprivation have a significant effect on our metabolism. The ... time of day to test for diseases such as ... , Researchers from the University of Surrey and The ... sleep deprivation, body clock disruption and metabolism, and discovered ...
(Date:7/10/2014)... even geckos and spiders can sit upside down forever. Nanophysics ... demonstrated this in an article just published in Physical ... benefit. , Geckos and spiders that seem to be able ... fascinated researchers worldwide for many years. We will soon be ... way as the gecko,s foot. But the fact is, sooner ...
(Date:1/15/2014)... akin to assembling a club sandwich at the ... researchers have succeeded in crafting a uniform, multi-walled ... foam commonly used in upholstered furniture and other ... polyurethane foam was reduced 35 percent compared with ...
Breaking Biology Technology:Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2
... Jan. 20, 2011 MedImmune,s Oncology group announced today ... broadly suppresses pathways that have been shown to play ... many solid tumors. The study, published in the February ... of the American Association for Cancer Research), suggests that ...
... Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, ... company that creates, develops and tests innovative HIV/AIDS vaccines, is ... Community Awards.  Dr. Robinson will be honored at the GaBio ... Atlanta,s Fox Theater. Dr. Robinson is the developer ...
... 2011 Reportlinker.com announces that a new market ... Hospital General Radiology Census ... is the most comprehensive European market report on ... IT systems (PACS) in European hospitals. Hospitals are ...
Cached Biology Technology:Investigational Compound Offers Novel Anti-IGF Approach To Inhibit Growth of Cancer Cells 2Investigational Compound Offers Novel Anti-IGF Approach To Inhibit Growth of Cancer Cells 3GeoVax Labs CSO Dr. Harriet L. Robinson to be Honored at 2011 Georgia Bio (GaBio) Community Awards Ceremony 2GeoVax Labs CSO Dr. Harriet L. Robinson to be Honored at 2011 Georgia Bio (GaBio) Community Awards Ceremony 3Reportlinker Adds Hospital General Radiology Census 2
(Date:7/11/2014)... Using spider toxins to study the proteins that let ... say they have stumbled upon a biological tactic that ... insect plagues in a safe and environmentally responsible way. ... be lethal for one species and harmless for a ... target specific pests without harming beneficial species like bees. ...
(Date:7/10/2014)... , June 30, 2014  Aware, Inc. (NASDAQ: ... software and services, previously announced on June 26, 2014 ... cash dividend of $1.75 per share, or approximately $40 ... of July 10, 2014 and a payment date of ... NASDAQ that it had set an ex-dividend date for ...
(Date:7/10/2014)... 2014 According to the new ... And Area), Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), ... Banking & Finance), and Geography - Global Trends & ... global Fingerprint Sensors Market is projected to cross $14.35 ... 16.8% from 2014 to 2020. Browse more ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... St. Jude Children,s Research Hospital have reported details of ... enzyme essential for the influenza virus, replication. Since all ... researchers believe their findings will yield drugs that can ... be resistant to current antiviral treatments. When new ...
... State University suggest that a "fight" between bacteria normally living ... another type of bacteria, may be linked to two types ... continues after the instigator bacteria have been cleared by the ... GSU Center for Inflammation, Immunity and Infection. That fight can ...
... UCLA stem cell researchers have found for the first ... endothelium, the place where blood stem cells are made ... lack of one transcription factor, a type of gene ... the precursors that normally generate blood stem and progenitor ...
Cached Biology News:Target for potent first-strike influenza drugs identified 2Target for potent first-strike influenza drugs identified 3Target for potent first-strike influenza drugs identified 4Embryonic blood vessels that make blood stem cells can also make beating heart muscles 2Embryonic blood vessels that make blood stem cells can also make beating heart muscles 3
... UNOsphere ion exchange ... supports with high binding ... support is a strong ... particle size of 120 ...
...
... Polyclonal Antibody against Aph-1a (Aph-1aL,S Loop ... gamma secretase is a multiprotein complex ... Pen-2; all four proteins are necessary ... secretase complex catalyzes cleavage of a ...
... Monoclonal Antibody Epitope: A ... Recommended Storage: Store vial ... contents and freeze at -20 C or below ... and thawing. Centrifuge product if not completely ...
Biology Products: